← Mechanisms of action
PMEL
SINGLE PROTEINHomo sapiens
Preferred name: Melanocyte protein PMEL ChEMBL ↗
Linked proteins
Drugs acting on this target (15)
| Active Pharmaceutical Ingredient | Mechanism Type ▲ | Approval Status | API Type | Mechanism of Action |
|---|---|---|---|---|
| afamelanotide (Scenesse) | Agonist | approved | Peptide | PMEL agonist |
| tebentafusp (Kimmtrak) | Binding agent | approved | Recombinant protein | PMEL binding agent |
| dendritic cell-gp100-mart-1 antigen vaccine | Immunity, active | experimental | Vaccine | PMEL immunity, active |
| gp-100 peptide vaccine | Immunity, active | experimental | Vaccine | PMEL immunity, active |
| gp100-fowlpox vaccine | Immunity, active | experimental | Vaccine | PMEL immunity, active |
| gp209-2m antigen | Immunity, active | experimental | Biological | PMEL immunity, active |
| mart-1, gp100, tyrosinase peptides | Immunity, active | experimental | Vaccine | PMEL immunity, active |
| mdx-1379 | Immunity, active | experimental | Vaccine | PMEL immunity, active |
| anti-gp 100:154 tcell receptor peripheral blood lymphocyte | Immunity, passive | experimental | Cell therapy | PMEL immunity, passive |
| autologous anti-gp 100:154-162 t-cell receptor gene-engineered peripheral blood lymphocytes | Immunity, passive | experimental | Cell therapy | PMEL immunity, passive |
| autologous anti-gp 100:154-162 t-cell receptor gene-engineered tumor infiltrating lymphocytes | Immunity, passive | experimental | Cell therapy | PMEL immunity, passive |
| gpa-trimar-t | Immunity, passive | experimental | Cell therapy | PMEL immunity, passive |
| lvgp120duocar-t cells | Immunity, passive | experimental | Cell therapy | PMEL immunity, passive |
| dyp688 | Inhibitor | experimental | mAb | PMEL inhibitor |
| bmx-001 | Other | experimental | Small molecule | PMEL other |